BindingDB Reactant_set_id Ligand SMILES Ligand InChI Ligand InChI Key BindingDB MonomerID BindingDB Ligand Name Target Name Target Source Organism According to Curator or DataSource Ki (nM) IC50 (nM) Kd (nM) EC50 (nM) kon (M-1-s-1) koff (s-1) pH Temp (C) Curation/DataSource Article DOI BindingDB Entry DOI PMID PubChem AID Patent Number Authors Date of publication Date in BindingDB Institution Link to Ligand in BindingDB Link to Target in BindingDB Link to Ligand-Target Pair in BindingDB Ligand HET ID in PDB PDB ID(s) for Ligand-Target Complex PubChem CID PubChem SID ChEBI ID of Ligand ChEMBL ID of Ligand DrugBank ID of Ligand IUPHAR_GRAC ID of Ligand KEGG ID of Ligand ZINC ID of Ligand Number of Protein Chains in Target (>1 implies a multichain complex) BindingDB Target Chain Sequence 1 PDB ID(s) of Target Chain 1 UniProt (SwissProt) Recommended Name of Target Chain 1 UniProt (SwissProt) Entry Name of Target Chain 1 UniProt (SwissProt) Primary ID of Target Chain 1 UniProt (SwissProt) Secondary ID(s) of Target Chain 1 UniProt (SwissProt) Alternative ID(s) of Target Chain 1 UniProt (TrEMBL) Submitted Name of Target Chain 1 UniProt (TrEMBL) Entry Name of Target Chain 1 UniProt (TrEMBL) Primary ID of Target Chain 1 UniProt (TrEMBL) Secondary ID(s) of Target Chain 1 UniProt (TrEMBL) Alternative ID(s) of Target Chain 1 BindingDB Target Chain Sequence 2 PDB ID(s) of Target Chain 2 UniProt (SwissProt) Recommended Name of Target Chain 2 UniProt (SwissProt) Entry Name of Target Chain 2 UniProt (SwissProt) Primary ID of Target Chain 2 UniProt (SwissProt) Secondary ID(s) of Target Chain 2 UniProt (SwissProt) Alternative ID(s) of Target Chain 2 UniProt (TrEMBL) Submitted Name of Target Chain 2 UniProt (TrEMBL) Entry Name of Target Chain 2 UniProt (TrEMBL) Primary ID of Target Chain 2 UniProt (TrEMBL) Secondary ID(s) of Target Chain 2 UniProt (TrEMBL) Alternative ID(s) of Target Chain 2 BindingDB Target Chain Sequence 3 PDB ID(s) of Target Chain 3 UniProt (SwissProt) Recommended Name of Target Chain 3 UniProt (SwissProt) Entry Name of Target Chain 3 UniProt (SwissProt) Primary ID of Target Chain 3 UniProt (SwissProt) Secondary ID(s) of Target Chain 3 UniProt (SwissProt) Alternative ID(s) of Target Chain 3 UniProt (TrEMBL) Submitted Name of Target Chain 3 UniProt (TrEMBL) Entry Name of Target Chain 3 UniProt (TrEMBL) Primary ID of Target Chain 3 UniProt (TrEMBL) Secondary ID(s) of Target Chain 3 UniProt (TrEMBL) Alternative ID(s) of Target Chain 3 BindingDB Target Chain Sequence 4 PDB ID(s) of Target Chain 4 UniProt (SwissProt) Recommended Name of Target Chain 4 UniProt (SwissProt) Entry Name of Target Chain 4 UniProt (SwissProt) Primary ID of Target Chain 4 UniProt (SwissProt) Secondary ID(s) of Target Chain 4 UniProt (SwissProt) Alternative ID(s) of Target Chain 4 UniProt (TrEMBL) Submitted Name of Target Chain 4 UniProt (TrEMBL) Entry Name of Target Chain 4 UniProt (TrEMBL) Primary ID of Target Chain 4 UniProt (TrEMBL) Secondary ID(s) of Target Chain 4 UniProt (TrEMBL) Alternative ID(s) of Target Chain 4 BindingDB Target Chain Sequence 5 PDB ID(s) of Target Chain 5 UniProt (SwissProt) Recommended Name of Target Chain 5 UniProt (SwissProt) Entry Name of Target Chain 5 UniProt (SwissProt) Primary ID of Target Chain 5 UniProt (SwissProt) Secondary ID(s) of Target Chain 5 UniProt (SwissProt) Alternative ID(s) of Target Chain 5 UniProt (TrEMBL) Submitted Name of Target Chain 5 UniProt (TrEMBL) Entry Name of Target Chain 5 UniProt (TrEMBL) Primary ID of Target Chain 5 UniProt (TrEMBL) Secondary ID(s) of Target Chain 5 UniProt (TrEMBL) Alternative ID(s) of Target Chain 5 BindingDB Target Chain Sequence 6 PDB ID(s) of Target Chain 6 UniProt (SwissProt) Recommended Name of Target Chain 6 UniProt (SwissProt) Entry Name of Target Chain 6 UniProt (SwissProt) Primary ID of Target Chain 6 UniProt (SwissProt) Secondary ID(s) of Target Chain 6 UniProt (SwissProt) Alternative ID(s) of Target Chain 6 UniProt (TrEMBL) Submitted Name of Target Chain 6 UniProt (TrEMBL) Entry Name of Target Chain 6 UniProt (TrEMBL) Primary ID of Target Chain 6 UniProt (TrEMBL) Secondary ID(s) of Target Chain 6 UniProt (TrEMBL) Alternative ID(s) of Target Chain 6 BindingDB Target Chain Sequence 7 PDB ID(s) of Target Chain 7 UniProt (SwissProt) Recommended Name of Target Chain 7 UniProt (SwissProt) Entry Name of Target Chain 7 UniProt (SwissProt) Primary ID of Target Chain 7 UniProt (SwissProt) Secondary ID(s) of Target Chain 7 UniProt (SwissProt) Alternative ID(s) of Target Chain 7 UniProt (TrEMBL) Submitted Name of Target Chain 7 UniProt (TrEMBL) Entry Name of Target Chain 7 UniProt (TrEMBL) Primary ID of Target Chain 7 UniProt (TrEMBL) Secondary ID(s) of Target Chain 7 UniProt (TrEMBL) Alternative ID(s) of Target Chain 7 BindingDB Target Chain Sequence 8 PDB ID(s) of Target Chain 8 UniProt (SwissProt) Recommended Name of Target Chain 8 UniProt (SwissProt) Entry Name of Target Chain 8 UniProt (SwissProt) Primary ID of Target Chain 8 UniProt (SwissProt) Secondary ID(s) of Target Chain 8 UniProt (SwissProt) Alternative ID(s) of Target Chain 8 UniProt (TrEMBL) Submitted Name of Target Chain 8 UniProt (TrEMBL) Entry Name of Target Chain 8 UniProt (TrEMBL) Primary ID of Target Chain 8 UniProt (TrEMBL) Secondary ID(s) of Target Chain 8 UniProt (TrEMBL) Alternative ID(s) of Target Chain 8 BindingDB Target Chain Sequence 9 PDB ID(s) of Target Chain 9 UniProt (SwissProt) Recommended Name of Target Chain 9 UniProt (SwissProt) Entry Name of Target Chain 9 UniProt (SwissProt) Primary ID of Target Chain 9 UniProt (SwissProt) Secondary ID(s) of Target Chain 9 UniProt (SwissProt) Alternative ID(s) of Target Chain 9 UniProt (TrEMBL) Submitted Name of Target Chain 9 UniProt (TrEMBL) Entry Name of Target Chain 9 UniProt (TrEMBL) Primary ID of Target Chain 9 UniProt (TrEMBL) Secondary ID(s) of Target Chain 9 UniProt (TrEMBL) Alternative ID(s) of Target Chain 9 BindingDB Target Chain Sequence 10 PDB ID(s) of Target Chain 10 UniProt (SwissProt) Recommended Name of Target Chain 10 UniProt (SwissProt) Entry Name of Target Chain 10 UniProt (SwissProt) Primary ID of Target Chain 10 UniProt (SwissProt) Secondary ID(s) of Target Chain 10 UniProt (SwissProt) Alternative ID(s) of Target Chain 10 UniProt (TrEMBL) Submitted Name of Target Chain 10 UniProt (TrEMBL) Entry Name of Target Chain 10 UniProt (TrEMBL) Primary ID of Target Chain 10 UniProt (TrEMBL) Secondary ID(s) of Target Chain 10 UniProt (TrEMBL) Alternative ID(s) of Target Chain 10 BindingDB Target Chain Sequence 11 PDB ID(s) of Target Chain 11 UniProt (SwissProt) Recommended Name of Target Chain 11 UniProt (SwissProt) Entry Name of Target Chain 11 UniProt (SwissProt) Primary ID of Target Chain 11 UniProt (SwissProt) Secondary ID(s) of Target Chain 11 UniProt (SwissProt) Alternative ID(s) of Target Chain 11 UniProt (TrEMBL) Submitted Name of Target Chain 11 UniProt (TrEMBL) Entry Name of Target Chain 11 UniProt (TrEMBL) Primary ID of Target Chain 11 UniProt (TrEMBL) Secondary ID(s) of Target Chain 11 UniProt (TrEMBL) Alternative ID(s) of Target Chain 11 BindingDB Target Chain Sequence 12 PDB ID(s) of Target Chain 12 UniProt (SwissProt) Recommended Name of Target Chain 12 UniProt (SwissProt) Entry Name of Target Chain 12 UniProt (SwissProt) Primary ID of Target Chain 12 UniProt (SwissProt) Secondary ID(s) of Target Chain 12 UniProt (SwissProt) Alternative ID(s) of Target Chain 12 UniProt (TrEMBL) Submitted Name of Target Chain 12 UniProt (TrEMBL) Entry Name of Target Chain 12 UniProt (TrEMBL) Primary ID of Target Chain 12 UniProt (TrEMBL) Secondary ID(s) of Target Chain 12 UniProt (TrEMBL) Alternative ID(s) of Target Chain 12 BindingDB Target Chain Sequence 13 PDB ID(s) of Target Chain 13 UniProt (SwissProt) Recommended Name of Target Chain 13 UniProt (SwissProt) Entry Name of Target Chain 13 UniProt (SwissProt) Primary ID of Target Chain 13 UniProt (SwissProt) Secondary ID(s) of Target Chain 13 UniProt (SwissProt) Alternative ID(s) of Target Chain 13 UniProt (TrEMBL) Submitted Name of Target Chain 13 UniProt (TrEMBL) Entry Name of Target Chain 13 UniProt (TrEMBL) Primary ID of Target Chain 13 UniProt (TrEMBL) Secondary ID(s) of Target Chain 13 UniProt (TrEMBL) Alternative ID(s) of Target Chain 13 BindingDB Target Chain Sequence 14 PDB ID(s) of Target Chain 14 UniProt (SwissProt) Recommended Name of Target Chain 14 UniProt (SwissProt) Entry Name of Target Chain 14 UniProt (SwissProt) Primary ID of Target Chain 14 UniProt (SwissProt) Secondary ID(s) of Target Chain 14 UniProt (SwissProt) Alternative ID(s) of Target Chain 14 UniProt (TrEMBL) Submitted Name of Target Chain 14 UniProt (TrEMBL) Entry Name of Target Chain 14 UniProt (TrEMBL) Primary ID of Target Chain 14 UniProt (TrEMBL) Secondary ID(s) of Target Chain 14 UniProt (TrEMBL) Alternative ID(s) of Target Chain 14 BindingDB Target Chain Sequence 15 PDB ID(s) of Target Chain 15 UniProt (SwissProt) Recommended Name of Target Chain 15 UniProt (SwissProt) Entry Name of Target Chain 15 UniProt (SwissProt) Primary ID of Target Chain 15 UniProt (SwissProt) Secondary ID(s) of Target Chain 15 UniProt (SwissProt) Alternative ID(s) of Target Chain 15 UniProt (TrEMBL) Submitted Name of Target Chain 15 UniProt (TrEMBL) Entry Name of Target Chain 15 UniProt (TrEMBL) Primary ID of Target Chain 15 UniProt (TrEMBL) Secondary ID(s) of Target Chain 15 UniProt (TrEMBL) Alternative ID(s) of Target Chain 15 BindingDB Target Chain Sequence 16 PDB ID(s) of Target Chain 16 UniProt (SwissProt) Recommended Name of Target Chain 16 UniProt (SwissProt) Entry Name of Target Chain 16 UniProt (SwissProt) Primary ID of Target Chain 16 UniProt (SwissProt) Secondary ID(s) of Target Chain 16 UniProt (SwissProt) Alternative ID(s) of Target Chain 16 UniProt (TrEMBL) Submitted Name of Target Chain 16 UniProt (TrEMBL) Entry Name of Target Chain 16 UniProt (TrEMBL) Primary ID of Target Chain 16 UniProt (TrEMBL) Secondary ID(s) of Target Chain 16 UniProt (TrEMBL) Alternative ID(s) of Target Chain 16 BindingDB Target Chain Sequence 17 PDB ID(s) of Target Chain 17 UniProt (SwissProt) Recommended Name of Target Chain 17 UniProt (SwissProt) Entry Name of Target Chain 17 UniProt (SwissProt) Primary ID of Target Chain 17 UniProt (SwissProt) Secondary ID(s) of Target Chain 17 UniProt (SwissProt) Alternative ID(s) of Target Chain 17 UniProt (TrEMBL) Submitted Name of Target Chain 17 UniProt (TrEMBL) Entry Name of Target Chain 17 UniProt (TrEMBL) Primary ID of Target Chain 17 UniProt (TrEMBL) Secondary ID(s) of Target Chain 17 UniProt (TrEMBL) Alternative ID(s) of Target Chain 17 BindingDB Target Chain Sequence 18 PDB ID(s) of Target Chain 18 UniProt (SwissProt) Recommended Name of Target Chain 18 UniProt (SwissProt) Entry Name of Target Chain 18 UniProt (SwissProt) Primary ID of Target Chain 18 UniProt (SwissProt) Secondary ID(s) of Target Chain 18 UniProt (SwissProt) Alternative ID(s) of Target Chain 18 UniProt (TrEMBL) Submitted Name of Target Chain 18 UniProt (TrEMBL) Entry Name of Target Chain 18 UniProt (TrEMBL) Primary ID of Target Chain 18 UniProt (TrEMBL) Secondary ID(s) of Target Chain 18 UniProt (TrEMBL) Alternative ID(s) of Target Chain 18 BindingDB Target Chain Sequence 19 PDB ID(s) of Target Chain 19 UniProt (SwissProt) Recommended Name of Target Chain 19 UniProt (SwissProt) Entry Name of Target Chain 19 UniProt (SwissProt) Primary ID of Target Chain 19 UniProt (SwissProt) Secondary ID(s) of Target Chain 19 UniProt (SwissProt) Alternative ID(s) of Target Chain 19 UniProt (TrEMBL) Submitted Name of Target Chain 19 UniProt (TrEMBL) Entry Name of Target Chain 19 UniProt (TrEMBL) Primary ID of Target Chain 19 UniProt (TrEMBL) Secondary ID(s) of Target Chain 19 UniProt (TrEMBL) Alternative ID(s) of Target Chain 19 BindingDB Target Chain Sequence 20 PDB ID(s) of Target Chain 20 UniProt (SwissProt) Recommended Name of Target Chain 20 UniProt (SwissProt) Entry Name of Target Chain 20 UniProt (SwissProt) Primary ID of Target Chain 20 UniProt (SwissProt) Secondary ID(s) of Target Chain 20 UniProt (SwissProt) Alternative ID(s) of Target Chain 20 UniProt (TrEMBL) Submitted Name of Target Chain 20 UniProt (TrEMBL) Entry Name of Target Chain 20 UniProt (TrEMBL) Primary ID of Target Chain 20 UniProt (TrEMBL) Secondary ID(s) of Target Chain 20 UniProt (TrEMBL) Alternative ID(s) of Target Chain 20 BindingDB Target Chain Sequence 21 PDB ID(s) of Target Chain 21 UniProt (SwissProt) Recommended Name of Target Chain 21 UniProt (SwissProt) Entry Name of Target Chain 21 UniProt (SwissProt) Primary ID of Target Chain 21 UniProt (SwissProt) Secondary ID(s) of Target Chain 21 UniProt (SwissProt) Alternative ID(s) of Target Chain 21 UniProt (TrEMBL) Submitted Name of Target Chain 21 UniProt (TrEMBL) Entry Name of Target Chain 21 UniProt (TrEMBL) Primary ID of Target Chain 21 UniProt (TrEMBL) Secondary ID(s) of Target Chain 21 UniProt (TrEMBL) Alternative ID(s) of Target Chain 21 BindingDB Target Chain Sequence 22 PDB ID(s) of Target Chain 22 UniProt (SwissProt) Recommended Name of Target Chain 22 UniProt (SwissProt) Entry Name of Target Chain 22 UniProt (SwissProt) Primary ID of Target Chain 22 UniProt (SwissProt) Secondary ID(s) of Target Chain 22 UniProt (SwissProt) Alternative ID(s) of Target Chain 22 UniProt (TrEMBL) Submitted Name of Target Chain 22 UniProt (TrEMBL) Entry Name of Target Chain 22 UniProt (TrEMBL) Primary ID of Target Chain 22 UniProt (TrEMBL) Secondary ID(s) of Target Chain 22 UniProt (TrEMBL) Alternative ID(s) of Target Chain 22 BindingDB Target Chain Sequence 23 PDB ID(s) of Target Chain 23 UniProt (SwissProt) Recommended Name of Target Chain 23 UniProt (SwissProt) Entry Name of Target Chain 23 UniProt (SwissProt) Primary ID of Target Chain 23 UniProt (SwissProt) Secondary ID(s) of Target Chain 23 UniProt (SwissProt) Alternative ID(s) of Target Chain 23 UniProt (TrEMBL) Submitted Name of Target Chain 23 UniProt (TrEMBL) Entry Name of Target Chain 23 UniProt (TrEMBL) Primary ID of Target Chain 23 UniProt (TrEMBL) Secondary ID(s) of Target Chain 23 UniProt (TrEMBL) Alternative ID(s) of Target Chain 23 BindingDB Target Chain Sequence 24 PDB ID(s) of Target Chain 24 UniProt (SwissProt) Recommended Name of Target Chain 24 UniProt (SwissProt) Entry Name of Target Chain 24 UniProt (SwissProt) Primary ID of Target Chain 24 UniProt (SwissProt) Secondary ID(s) of Target Chain 24 UniProt (SwissProt) Alternative ID(s) of Target Chain 24 UniProt (TrEMBL) Submitted Name of Target Chain 24 UniProt (TrEMBL) Entry Name of Target Chain 24 UniProt (TrEMBL) Primary ID of Target Chain 24 UniProt (TrEMBL) Secondary ID(s) of Target Chain 24 UniProt (TrEMBL) Alternative ID(s) of Target Chain 24 BindingDB Target Chain Sequence 25 PDB ID(s) of Target Chain 25 UniProt (SwissProt) Recommended Name of Target Chain 25 UniProt (SwissProt) Entry Name of Target Chain 25 UniProt (SwissProt) Primary ID of Target Chain 25 UniProt (SwissProt) Secondary ID(s) of Target Chain 25 UniProt (SwissProt) Alternative ID(s) of Target Chain 25 UniProt (TrEMBL) Submitted Name of Target Chain 25 UniProt (TrEMBL) Entry Name of Target Chain 25 UniProt (TrEMBL) Primary ID of Target Chain 25 UniProt (TrEMBL) Secondary ID(s) of Target Chain 25 UniProt (TrEMBL) Alternative ID(s) of Target Chain 25 BindingDB Target Chain Sequence 26 PDB ID(s) of Target Chain 26 UniProt (SwissProt) Recommended Name of Target Chain 26 UniProt (SwissProt) Entry Name of Target Chain 26 UniProt (SwissProt) Primary ID of Target Chain 26 UniProt (SwissProt) Secondary ID(s) of Target Chain 26 UniProt (SwissProt) Alternative ID(s) of Target Chain 26 UniProt (TrEMBL) Submitted Name of Target Chain 26 UniProt (TrEMBL) Entry Name of Target Chain 26 UniProt (TrEMBL) Primary ID of Target Chain 26 UniProt (TrEMBL) Secondary ID(s) of Target Chain 26 UniProt (TrEMBL) Alternative ID(s) of Target Chain 26 BindingDB Target Chain Sequence 27 PDB ID(s) of Target Chain 27 UniProt (SwissProt) Recommended Name of Target Chain 27 UniProt (SwissProt) Entry Name of Target Chain 27 UniProt (SwissProt) Primary ID of Target Chain 27 UniProt (SwissProt) Secondary ID(s) of Target Chain 27 UniProt (SwissProt) Alternative ID(s) of Target Chain 27 UniProt (TrEMBL) Submitted Name of Target Chain 27 UniProt (TrEMBL) Entry Name of Target Chain 27 UniProt (TrEMBL) Primary ID of Target Chain 27 UniProt (TrEMBL) Secondary ID(s) of Target Chain 27 UniProt (TrEMBL) Alternative ID(s) of Target Chain 27 BindingDB Target Chain Sequence 28 PDB ID(s) of Target Chain 28 UniProt (SwissProt) Recommended Name of Target Chain 28 UniProt (SwissProt) Entry Name of Target Chain 28 UniProt (SwissProt) Primary ID of Target Chain 28 UniProt (SwissProt) Secondary ID(s) of Target Chain 28 UniProt (SwissProt) Alternative ID(s) of Target Chain 28 UniProt (TrEMBL) Submitted Name of Target Chain 28 UniProt (TrEMBL) Entry Name of Target Chain 28 UniProt (TrEMBL) Primary ID of Target Chain 28 UniProt (TrEMBL) Secondary ID(s) of Target Chain 28 UniProt (TrEMBL) Alternative ID(s) of Target Chain 28 BindingDB Target Chain Sequence 29 PDB ID(s) of Target Chain 29 UniProt (SwissProt) Recommended Name of Target Chain 29 UniProt (SwissProt) Entry Name of Target Chain 29 UniProt (SwissProt) Primary ID of Target Chain 29 UniProt (SwissProt) Secondary ID(s) of Target Chain 29 UniProt (SwissProt) Alternative ID(s) of Target Chain 29 UniProt (TrEMBL) Submitted Name of Target Chain 29 UniProt (TrEMBL) Entry Name of Target Chain 29 UniProt (TrEMBL) Primary ID of Target Chain 29 UniProt (TrEMBL) Secondary ID(s) of Target Chain 29 UniProt (TrEMBL) Alternative ID(s) of Target Chain 29 BindingDB Target Chain Sequence 30 PDB ID(s) of Target Chain 30 UniProt (SwissProt) Recommended Name of Target Chain 30 UniProt (SwissProt) Entry Name of Target Chain 30 UniProt (SwissProt) Primary ID of Target Chain 30 UniProt (SwissProt) Secondary ID(s) of Target Chain 30 UniProt (SwissProt) Alternative ID(s) of Target Chain 30 UniProt (TrEMBL) Submitted Name of Target Chain 30 UniProt (TrEMBL) Entry Name of Target Chain 30 UniProt (TrEMBL) Primary ID of Target Chain 30 UniProt (TrEMBL) Secondary ID(s) of Target Chain 30 UniProt (TrEMBL) Alternative ID(s) of Target Chain 30 BindingDB Target Chain Sequence 31 PDB ID(s) of Target Chain 31 UniProt (SwissProt) Recommended Name of Target Chain 31 UniProt (SwissProt) Entry Name of Target Chain 31 UniProt (SwissProt) Primary ID of Target Chain 31 UniProt (SwissProt) Secondary ID(s) of Target Chain 31 UniProt (SwissProt) Alternative ID(s) of Target Chain 31 UniProt (TrEMBL) Submitted Name of Target Chain 31 UniProt (TrEMBL) Entry Name of Target Chain 31 UniProt (TrEMBL) Primary ID of Target Chain 31 UniProt (TrEMBL) Secondary ID(s) of Target Chain 31 UniProt (TrEMBL) Alternative ID(s) of Target Chain 31 BindingDB Target Chain Sequence 32 PDB ID(s) of Target Chain 32 UniProt (SwissProt) Recommended Name of Target Chain 32 UniProt (SwissProt) Entry Name of Target Chain 32 UniProt (SwissProt) Primary ID of Target Chain 32 UniProt (SwissProt) Secondary ID(s) of Target Chain 32 UniProt (SwissProt) Alternative ID(s) of Target Chain 32 UniProt (TrEMBL) Submitted Name of Target Chain 32 UniProt (TrEMBL) Entry Name of Target Chain 32 UniProt (TrEMBL) Primary ID of Target Chain 32 UniProt (TrEMBL) Secondary ID(s) of Target Chain 32 UniProt (TrEMBL) Alternative ID(s) of Target Chain 32 BindingDB Target Chain Sequence 33 PDB ID(s) of Target Chain 33 UniProt (SwissProt) Recommended Name of Target Chain 33 UniProt (SwissProt) Entry Name of Target Chain 33 UniProt (SwissProt) Primary ID of Target Chain 33 UniProt (SwissProt) Secondary ID(s) of Target Chain 33 UniProt (SwissProt) Alternative ID(s) of Target Chain 33 UniProt (TrEMBL) Submitted Name of Target Chain 33 UniProt (TrEMBL) Entry Name of Target Chain 33 UniProt (TrEMBL) Primary ID of Target Chain 33 UniProt (TrEMBL) Secondary ID(s) of Target Chain 33 UniProt (TrEMBL) Alternative ID(s) of Target Chain 33 BindingDB Target Chain Sequence 34 PDB ID(s) of Target Chain 34 UniProt (SwissProt) Recommended Name of Target Chain 34 UniProt (SwissProt) Entry Name of Target Chain 34 UniProt (SwissProt) Primary ID of Target Chain 34 UniProt (SwissProt) Secondary ID(s) of Target Chain 34 UniProt (SwissProt) Alternative ID(s) of Target Chain 34 UniProt (TrEMBL) Submitted Name of Target Chain 34 UniProt (TrEMBL) Entry Name of Target Chain 34 UniProt (TrEMBL) Primary ID of Target Chain 34 UniProt (TrEMBL) Secondary ID(s) of Target Chain 34 UniProt (TrEMBL) Alternative ID(s) of Target Chain 34 BindingDB Target Chain Sequence 35 PDB ID(s) of Target Chain 35 UniProt (SwissProt) Recommended Name of Target Chain 35 UniProt (SwissProt) Entry Name of Target Chain 35 UniProt (SwissProt) Primary ID of Target Chain 35 UniProt (SwissProt) Secondary ID(s) of Target Chain 35 UniProt (SwissProt) Alternative ID(s) of Target Chain 35 UniProt (TrEMBL) Submitted Name of Target Chain 35 UniProt (TrEMBL) Entry Name of Target Chain 35 UniProt (TrEMBL) Primary ID of Target Chain 35 UniProt (TrEMBL) Secondary ID(s) of Target Chain 35 UniProt (TrEMBL) Alternative ID(s) of Target Chain 35 BindingDB Target Chain Sequence 36 PDB ID(s) of Target Chain 36 UniProt (SwissProt) Recommended Name of Target Chain 36 UniProt (SwissProt) Entry Name of Target Chain 36 UniProt (SwissProt) Primary ID of Target Chain 36 UniProt (SwissProt) Secondary ID(s) of Target Chain 36 UniProt (SwissProt) Alternative ID(s) of Target Chain 36 UniProt (TrEMBL) Submitted Name of Target Chain 36 UniProt (TrEMBL) Entry Name of Target Chain 36 UniProt (TrEMBL) Primary ID of Target Chain 36 UniProt (TrEMBL) Secondary ID(s) of Target Chain 36 UniProt (TrEMBL) Alternative ID(s) of Target Chain 36 BindingDB Target Chain Sequence 37 PDB ID(s) of Target Chain 37 UniProt (SwissProt) Recommended Name of Target Chain 37 UniProt (SwissProt) Entry Name of Target Chain 37 UniProt (SwissProt) Primary ID of Target Chain 37 UniProt (SwissProt) Secondary ID(s) of Target Chain 37 UniProt (SwissProt) Alternative ID(s) of Target Chain 37 UniProt (TrEMBL) Submitted Name of Target Chain 37 UniProt (TrEMBL) Entry Name of Target Chain 37 UniProt (TrEMBL) Primary ID of Target Chain 37 UniProt (TrEMBL) Secondary ID(s) of Target Chain 37 UniProt (TrEMBL) Alternative ID(s) of Target Chain 37 BindingDB Target Chain Sequence 38 PDB ID(s) of Target Chain 38 UniProt (SwissProt) Recommended Name of Target Chain 38 UniProt (SwissProt) Entry Name of Target Chain 38 UniProt (SwissProt) Primary ID of Target Chain 38 UniProt (SwissProt) Secondary ID(s) of Target Chain 38 UniProt (SwissProt) Alternative ID(s) of Target Chain 38 UniProt (TrEMBL) Submitted Name of Target Chain 38 UniProt (TrEMBL) Entry Name of Target Chain 38 UniProt (TrEMBL) Primary ID of Target Chain 38 UniProt (TrEMBL) Secondary ID(s) of Target Chain 38 UniProt (TrEMBL) Alternative ID(s) of Target Chain 38 BindingDB Target Chain Sequence 39 PDB ID(s) of Target Chain 39 UniProt (SwissProt) Recommended Name of Target Chain 39 UniProt (SwissProt) Entry Name of Target Chain 39 UniProt (SwissProt) Primary ID of Target Chain 39 UniProt (SwissProt) Secondary ID(s) of Target Chain 39 UniProt (SwissProt) Alternative ID(s) of Target Chain 39 UniProt (TrEMBL) Submitted Name of Target Chain 39 UniProt (TrEMBL) Entry Name of Target Chain 39 UniProt (TrEMBL) Primary ID of Target Chain 39 UniProt (TrEMBL) Secondary ID(s) of Target Chain 39 UniProt (TrEMBL) Alternative ID(s) of Target Chain 39 BindingDB Target Chain Sequence 40 PDB ID(s) of Target Chain 40 UniProt (SwissProt) Recommended Name of Target Chain 40 UniProt (SwissProt) Entry Name of Target Chain 40 UniProt (SwissProt) Primary ID of Target Chain 40 UniProt (SwissProt) Secondary ID(s) of Target Chain 40 UniProt (SwissProt) Alternative ID(s) of Target Chain 40 UniProt (TrEMBL) Submitted Name of Target Chain 40 UniProt (TrEMBL) Entry Name of Target Chain 40 UniProt (TrEMBL) Primary ID of Target Chain 40 UniProt (TrEMBL) Secondary ID(s) of Target Chain 40 UniProt (TrEMBL) Alternative ID(s) of Target Chain 40 BindingDB Target Chain Sequence 41 PDB ID(s) of Target Chain 41 UniProt (SwissProt) Recommended Name of Target Chain 41 UniProt (SwissProt) Entry Name of Target Chain 41 UniProt (SwissProt) Primary ID of Target Chain 41 UniProt (SwissProt) Secondary ID(s) of Target Chain 41 UniProt (SwissProt) Alternative ID(s) of Target Chain 41 UniProt (TrEMBL) Submitted Name of Target Chain 41 UniProt (TrEMBL) Entry Name of Target Chain 41 UniProt (TrEMBL) Primary ID of Target Chain 41 UniProt (TrEMBL) Secondary ID(s) of Target Chain 41 UniProt (TrEMBL) Alternative ID(s) of Target Chain 41 BindingDB Target Chain Sequence 42 PDB ID(s) of Target Chain 42 UniProt (SwissProt) Recommended Name of Target Chain 42 UniProt (SwissProt) Entry Name of Target Chain 42 UniProt (SwissProt) Primary ID of Target Chain 42 UniProt (SwissProt) Secondary ID(s) of Target Chain 42 UniProt (SwissProt) Alternative ID(s) of Target Chain 42 UniProt (TrEMBL) Submitted Name of Target Chain 42 UniProt (TrEMBL) Entry Name of Target Chain 42 UniProt (TrEMBL) Primary ID of Target Chain 42 UniProt (TrEMBL) Secondary ID(s) of Target Chain 42 UniProt (TrEMBL) Alternative ID(s) of Target Chain 42 BindingDB Target Chain Sequence 43 PDB ID(s) of Target Chain 43 UniProt (SwissProt) Recommended Name of Target Chain 43 UniProt (SwissProt) Entry Name of Target Chain 43 UniProt (SwissProt) Primary ID of Target Chain 43 UniProt (SwissProt) Secondary ID(s) of Target Chain 43 UniProt (SwissProt) Alternative ID(s) of Target Chain 43 UniProt (TrEMBL) Submitted Name of Target Chain 43 UniProt (TrEMBL) Entry Name of Target Chain 43 UniProt (TrEMBL) Primary ID of Target Chain 43 UniProt (TrEMBL) Secondary ID(s) of Target Chain 43 UniProt (TrEMBL) Alternative ID(s) of Target Chain 43 BindingDB Target Chain Sequence 44 PDB ID(s) of Target Chain 44 UniProt (SwissProt) Recommended Name of Target Chain 44 UniProt (SwissProt) Entry Name of Target Chain 44 UniProt (SwissProt) Primary ID of Target Chain 44 UniProt (SwissProt) Secondary ID(s) of Target Chain 44 UniProt (SwissProt) Alternative ID(s) of Target Chain 44 UniProt (TrEMBL) Submitted Name of Target Chain 44 UniProt (TrEMBL) Entry Name of Target Chain 44 UniProt (TrEMBL) Primary ID of Target Chain 44 UniProt (TrEMBL) Secondary ID(s) of Target Chain 44 UniProt (TrEMBL) Alternative ID(s) of Target Chain 44 BindingDB Target Chain Sequence 45 PDB ID(s) of Target Chain 45 UniProt (SwissProt) Recommended Name of Target Chain 45 UniProt (SwissProt) Entry Name of Target Chain 45 UniProt (SwissProt) Primary ID of Target Chain 45 UniProt (SwissProt) Secondary ID(s) of Target Chain 45 UniProt (SwissProt) Alternative ID(s) of Target Chain 45 UniProt (TrEMBL) Submitted Name of Target Chain 45 UniProt (TrEMBL) Entry Name of Target Chain 45 UniProt (TrEMBL) Primary ID of Target Chain 45 UniProt (TrEMBL) Secondary ID(s) of Target Chain 45 UniProt (TrEMBL) Alternative ID(s) of Target Chain 45 BindingDB Target Chain Sequence 46 PDB ID(s) of Target Chain 46 UniProt (SwissProt) Recommended Name of Target Chain 46 UniProt (SwissProt) Entry Name of Target Chain 46 UniProt (SwissProt) Primary ID of Target Chain 46 UniProt (SwissProt) Secondary ID(s) of Target Chain 46 UniProt (SwissProt) Alternative ID(s) of Target Chain 46 UniProt (TrEMBL) Submitted Name of Target Chain 46 UniProt (TrEMBL) Entry Name of Target Chain 46 UniProt (TrEMBL) Primary ID of Target Chain 46 UniProt (TrEMBL) Secondary ID(s) of Target Chain 46 UniProt (TrEMBL) Alternative ID(s) of Target Chain 46 BindingDB Target Chain Sequence 47 PDB ID(s) of Target Chain 47 UniProt (SwissProt) Recommended Name of Target Chain 47 UniProt (SwissProt) Entry Name of Target Chain 47 UniProt (SwissProt) Primary ID of Target Chain 47 UniProt (SwissProt) Secondary ID(s) of Target Chain 47 UniProt (SwissProt) Alternative ID(s) of Target Chain 47 UniProt (TrEMBL) Submitted Name of Target Chain 47 UniProt (TrEMBL) Entry Name of Target Chain 47 UniProt (TrEMBL) Primary ID of Target Chain 47 UniProt (TrEMBL) Secondary ID(s) of Target Chain 47 UniProt (TrEMBL) Alternative ID(s) of Target Chain 47 BindingDB Target Chain Sequence 48 PDB ID(s) of Target Chain 48 UniProt (SwissProt) Recommended Name of Target Chain 48 UniProt (SwissProt) Entry Name of Target Chain 48 UniProt (SwissProt) Primary ID of Target Chain 48 UniProt (SwissProt) Secondary ID(s) of Target Chain 48 UniProt (SwissProt) Alternative ID(s) of Target Chain 48 UniProt (TrEMBL) Submitted Name of Target Chain 48 UniProt (TrEMBL) Entry Name of Target Chain 48 UniProt (TrEMBL) Primary ID of Target Chain 48 UniProt (TrEMBL) Secondary ID(s) of Target Chain 48 UniProt (TrEMBL) Alternative ID(s) of Target Chain 48 BindingDB Target Chain Sequence 49 PDB ID(s) of Target Chain 49 UniProt (SwissProt) Recommended Name of Target Chain 49 UniProt (SwissProt) Entry Name of Target Chain 49 UniProt (SwissProt) Primary ID of Target Chain 49 UniProt (SwissProt) Secondary ID(s) of Target Chain 49 UniProt (SwissProt) Alternative ID(s) of Target Chain 49 UniProt (TrEMBL) Submitted Name of Target Chain 49 UniProt (TrEMBL) Entry Name of Target Chain 49 UniProt (TrEMBL) Primary ID of Target Chain 49 UniProt (TrEMBL) Secondary ID(s) of Target Chain 49 UniProt (TrEMBL) Alternative ID(s) of Target Chain 49 BindingDB Target Chain Sequence 50 PDB ID(s) of Target Chain 50 UniProt (SwissProt) Recommended Name of Target Chain 50 UniProt (SwissProt) Entry Name of Target Chain 50 UniProt (SwissProt) Primary ID of Target Chain 50 UniProt (SwissProt) Secondary ID(s) of Target Chain 50 UniProt (SwissProt) Alternative ID(s) of Target Chain 50 UniProt (TrEMBL) Submitted Name of Target Chain 50 UniProt (TrEMBL) Entry Name of Target Chain 50 UniProt (TrEMBL) Primary ID of Target Chain 50 UniProt (TrEMBL) Secondary ID(s) of Target Chain 50 UniProt (TrEMBL) Alternative ID(s) of Target Chain 50 582579 CCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc2c(cc1=O)-c1cc(Cl)ccc1CNC2=O |$;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C24H20ClN3O5/c1-2-20(23(31)27-16-7-4-13(5-8-16)24(32)33)28-12-19-18(10-21(28)29)17-9-15(25)6-3-14(17)11-26-22(19)30/h3-10,12,20H,2,11H2,1H3,(H,26,30)(H,27,31)(H,32,33) SKGWZOVDJYWHAV-UHFFFAOYSA-N 303783 4-{[2-(10-Chloro-2,5-dioxo-2,5,6,7-tetrahydro-3H-pyrido[3,4-d][2]benzazepin-3-yl)butanoyl]amino}benzoic acid (Stereoisomer Mixture)::US10138236, Example 1 Coagulation factor XI Human 420 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303783 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303783&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 121247947 381752514 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582580 CCC(C(=O)Nc1ccc(cc1)-c1noc(=O)[nH]1)n1cc2c(cc1=O)-c1cc(Cl)ccc1CNC2=O |$;;;;;HN;;;;;;;;;;;;HN;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C25H20ClN5O5/c1-2-20(24(34)28-16-7-4-13(5-8-16)22-29-25(35)36-30-22)31-12-19-18(10-21(31)32)17-9-15(26)6-3-14(17)11-27-23(19)33/h3-10,12,20H,2,11H2,1H3,(H,27,33)(H,28,34)(H,29,30,35) ISVJPGYUZXHMRW-UHFFFAOYSA-N 303784 2-(10-Chloro-2,5-dioxo-2,5,6,7-tetrahydro-3H-pyrido[3,4-d][2]benzazepin-3-yl)-N-[4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl]butanamide (Stereoisomer Mixture)::US10138236, Example 2 Coagulation factor XI Human 280 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303784 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303784&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 137135831 381752515 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582581 CCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc2c(cc1=O)-c1cc(Cl)ccc1C1(CC1)NC2=O |$;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C26H22ClN3O5/c1-2-21(24(33)28-16-6-3-14(4-7-16)25(34)35)30-13-19-17(12-22(30)31)18-11-15(27)5-8-20(18)26(9-10-26)29-23(19)32/h3-8,11-13,21H,2,9-10H2,1H3,(H,28,33)(H,29,32)(H,34,35) KCGMSSQFQFMUQQ-UHFFFAOYSA-N 303785 4-{[2-(10′-Chloro-2′,5′-dioxo-5′,6′-dihydrospiro[cyclopropane-1,7′-pyrido[3,4-d][2]benzazepine]-3′(2′H)-yl)butanoyl]amino}benzoic acid (Stereoisomer Mixture)::US10138236, Example 3 Coagulation factor XI Human 180 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303785 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303785&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 121247954 381752516 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582582 OC(=O)c1ccc(NC(=O)Cn2cc3c(cc2=O)-c2cc(Cl)ccc2CCNC3=O)cc1 |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;HN;;;;$| InChI=1S/C23H18ClN3O5/c24-15-4-1-13-7-8-25-22(30)19-11-27(21(29)10-18(19)17(13)9-15)12-20(28)26-16-5-2-14(3-6-16)23(31)32/h1-6,9-11H,7-8,12H2,(H,25,30)(H,26,28)(H,31,32) YHCVQIPIKWVWDD-UHFFFAOYSA-N 303786 4-{[(11-Chloro-2,5-dioxo-5,6,7,8-tetrahydropyrido[3,4-e][3]benzazocin-3(2H)-yl)acetyl]amino}benzoic acid::US10138236, Example 4 Coagulation factor XI Human 720 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303786 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303786&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 121248291 381752517 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582583 Clc1ccc2CCNC(=O)c3cn(CC(=O)Nc4ccc(cc4)-c4noc(=O)[nH]4)c(=O)cc3-c2c1 |$;;;;;;;HN;;;;;;;;;HN;;;;;;;;;;;;HN;;;;;;$| InChI=1S/C24H18ClN5O5/c25-15-4-1-13-7-8-26-23(33)19-11-30(21(32)10-18(19)17(13)9-15)12-20(31)27-16-5-2-14(3-6-16)22-28-24(34)35-29-22/h1-6,9-11H,7-8,12H2,(H,26,33)(H,27,31)(H,28,29,34) UPXBPQOTPKHXLR-UHFFFAOYSA-N 303787 2-(11-Chloro-2,5-dioxo-5,6,7,8-tetrahydropyrido[3,4-e][3]benzazocin-3(2H)-yl)-N-[4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl]acetamide::US10138236, Example 5 Coagulation factor XI Human 350 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303787 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303787&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 137135834 381752518 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582584 CCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc2c(cc1=O)-c1cc(Cl)ccc1CCNC2=O |$;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C25H22ClN3O5/c1-2-21(24(32)28-17-7-4-15(5-8-17)25(33)34)29-13-20-19(12-22(29)30)18-11-16(26)6-3-14(18)9-10-27-23(20)31/h3-8,11-13,21H,2,9-10H2,1H3,(H,27,31)(H,28,32)(H,33,34) QTIMNPKDOKJHOR-UHFFFAOYSA-N 303788 4-{[2-(11-Chloro-2,5-dioxo-5,6,7,8-tetrahydropyrido[3,4-e][3]benzazocin-3(2H)-yl)butanoyl]amino}benzoic acid (Stereoisomer Mixture)::US10138236, Example 6 Coagulation factor XI Human 28.0 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303788 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303788&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 121247931 381752519 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582585 CCC(C(=O)Nc1ccc(cc1)-c1noc(=O)[nH]1)n1cc2c(cc1=O)-c1cc(Cl)ccc1CCNC2=O |$;;;;;HN;;;;;;;;;;;;HN;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C26H22ClN5O5/c1-2-21(25(35)29-17-7-4-15(5-8-17)23-30-26(36)37-31-23)32-13-20-19(12-22(32)33)18-11-16(27)6-3-14(18)9-10-28-24(20)34/h3-8,11-13,21H,2,9-10H2,1H3,(H,28,34)(H,29,35)(H,30,31,36) JIKIDROQLCJHCV-UHFFFAOYSA-N 303789 2-(11-Chloro-2,5-dioxo-5,6,7,8-tetrahydropyrido[3,4-e][3]benzazocin-3(2H)-yl)-N-[4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl]butanamide (Stereoisomer Mixture)::US10138236, Example 7 Coagulation factor XI Human 44.0 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303789 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303789&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 137135835 381752520 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582586 CC(C)CC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc2c(cc1=O)-c1cc(Cl)ccc1CCNC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C27H26ClN3O5/c1-15(2)11-23(26(34)30-19-7-4-17(5-8-19)27(35)36)31-14-22-21(13-24(31)32)20-12-18(28)6-3-16(20)9-10-29-25(22)33/h3-8,12-15,23H,9-11H2,1-2H3,(H,29,33)(H,30,34)(H,35,36) NUGGTDIZDRCFKE-UHFFFAOYSA-N 303790 4-{[2-(11-Chloro-2,5-dioxo-5,6,7,8-tetrahydropyrido[3,4-e][3]benzazocin-3(2H)-yl)-4-methylpentanoyl]amino}benzoic acid (Stereoisomer Mixture)::US10138236, Example 8 Coagulation factor XI Human 36.0 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303790 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303790&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 130446977 381752521 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582587 CC(C)CC(C(=O)Nc1ccc(cc1)-c1noc(=O)[nH]1)n1cc2c(cc1=O)-c1cc(Cl)ccc1CCNC2=O |$;;;;;;;HN;;;;;;;;;;;;HN;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C28H26ClN5O5/c1-15(2)11-23(27(37)31-19-7-4-17(5-8-19)25-32-28(38)39-33-25)34-14-22-21(13-24(34)35)20-12-18(29)6-3-16(20)9-10-30-26(22)36/h3-8,12-15,23H,9-11H2,1-2H3,(H,30,36)(H,31,37)(H,32,33,38) XMCVCGZQOZMSLX-UHFFFAOYSA-N 303791 2-(11-Chloro-2,5-dioxo-5,6,7,8-tetrahydropyrido[3,4-e][3]benzazocin-3(2H)-yl)-4-methyl-N-[4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl]pentanamide (Stereoisomer Mixture)::US10138236, Example 9 Coagulation factor XI Human 140 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303791 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303791&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 137198183 381752522 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582588 CCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C27H24ClN3O5/c1-2-22(25(34)29-18-7-4-15(5-8-18)26(35)36)31-14-21-20(12-23(31)32)19-11-17(28)6-3-16(19)13-27(9-10-27)30-24(21)33/h3-8,11-12,14,22H,2,9-10,13H2,1H3,(H,29,34)(H,30,33)(H,35,36) SLECLLUJAMLAFG-UHFFFAOYSA-N 303792 4-{[2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)butanoyl]amino}benzoic acid (Stereoisomer Mixture)::US10138236, Example 10 Coagulation factor XI Human 7.70 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303792 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303792&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 121248294 381752523 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582589 CCC(C(=O)Nc1ccc(cc1)-c1noc(=O)[nH]1)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;HN;;;;;;;;;;;;HN;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C28H24ClN5O5/c1-2-22(26(37)30-18-7-4-15(5-8-18)24-31-27(38)39-33-24)34-14-21-20(12-23(34)35)19-11-17(29)6-3-16(19)13-28(9-10-28)32-25(21)36/h3-8,11-12,14,22H,2,9-10,13H2,1H3,(H,30,37)(H,32,36)(H,31,33,38) ZUPOJXBRFRVQEB-UHFFFAOYSA-N 303793 2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-N-[4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl]butanamide (Stereoisomer Mixture)::US10138236, Example 11 Coagulation factor XI Human 16.0 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303793 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303793&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 137135832 381752524 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582590 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C28H26ClN3O6/c1-38-11-8-23(26(35)30-19-6-3-16(4-7-19)27(36)37)32-15-22-21(13-24(32)33)20-12-18(29)5-2-17(20)14-28(9-10-28)31-25(22)34/h2-7,12-13,15,23H,8-11,14H2,1H3,(H,30,35)(H,31,34)(H,36,37) XQFUNGTWELOWHU-UHFFFAOYSA-N 303794 4-{[2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-4-methoxybutanoyl]amino}benzoic acid (Stereoisomer Mixture)::US10138236, Example 12 Coagulation factor XI Human 1.90 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303794 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303794&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 121247878 381752525 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582591 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C28H26ClFN4O5/c1-39-9-6-23(27(38)32-17-4-5-18(25(31)36)22(30)11-17)34-14-21-20(12-24(34)35)19-10-16(29)3-2-15(19)13-28(7-8-28)33-26(21)37/h2-5,10-12,14,23H,6-9,13H2,1H3,(H2,31,36)(H,32,38)(H,33,37) BPCDFQQYUDAWIS-UHFFFAOYSA-N 303795 4-{[2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-4-methoxybutanoyl]amino}-2-fluorobenzamide (Stereoisomer Mixture)::US10138236, Example 13 Coagulation factor XI Human 27.0 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303795 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303795&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 121247960 381752526 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582592 COCCC(C(=O)Nc1ccc2[nH]c(=O)[nH]c2c1)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;;;HN;;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C28H26ClN5O5/c1-39-9-6-23(26(37)30-17-4-5-21-22(11-17)32-27(38)31-21)34-14-20-19(12-24(34)35)18-10-16(29)3-2-15(18)13-28(7-8-28)33-25(20)36/h2-5,10-12,14,23H,6-9,13H2,1H3,(H,30,37)(H,33,36)(H2,31,32,38) XTKDBGPBQRDAJF-UHFFFAOYSA-N 303796 2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-4-methoxy-N-(2-oxo-2,3-dihydro-1H-benzimidazol-5-yl)butanamide (Stereoisomer Mixture)::US10138236, Example 14 Coagulation factor XI Human 18.0 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303796 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303796&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 121248288 381752527 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582593 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C29H28ClN5O4/c1-34-15-18-11-20(5-6-24(18)33-34)31-28(38)25(7-10-39-2)35-16-23-22(13-26(35)36)21-12-19(30)4-3-17(21)14-29(8-9-29)32-27(23)37/h3-6,11-13,15-16,25H,7-10,14H2,1-2H3,(H,31,38)(H,32,37) KLDJEVDWFKQWAE-UHFFFAOYSA-N 303797 2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Stereoisomer Mixture)::US10138236, Example 15 Coagulation factor XI Human 8.20 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303797 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303797&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 121248295 381752528 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582594 COCCC(C(=O)Nc1ccn2nccc2c1)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C28H26ClN5O4/c1-38-11-6-24(27(37)31-19-5-10-34-20(13-19)4-9-30-34)33-16-23-22(14-25(33)35)21-12-18(29)3-2-17(21)15-28(7-8-28)32-26(23)36/h2-5,9-10,12-14,16,24H,6-8,11,15H2,1H3,(H,31,37)(H,32,36) FJPYLKOGJOUMKM-UHFFFAOYSA-N 303798 2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-4-methoxy-N-(pyrazolo[1,5-a]pyridin-5-yl)butanamide (Stereoisomer Mixture)::US10138236, Example 16 Coagulation factor XI Human 11.0 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303798 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303798&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 121248130 381752529 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582595 COCCC(C(=O)Nc1ccc2nccn2c1)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C28H26ClN5O4/c1-38-11-6-23(27(37)31-19-4-5-24-30-9-10-33(24)15-19)34-16-22-21(13-25(34)35)20-12-18(29)3-2-17(20)14-28(7-8-28)32-26(22)36/h2-5,9-10,12-13,15-16,23H,6-8,11,14H2,1H3,(H,31,37)(H,32,36) LJUIKBIWSCZQIA-UHFFFAOYSA-N 303799 2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-N-(imidazo[1,2-a]pyridin-6-yl)-4-methoxybutanamide (Stereoisomer Mixture)::US10138236, Example 17 Coagulation factor XI Human 44.0 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303799 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303799&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 121247961 381752530 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582596 COCCC(C(=O)Nc1ccc2[nH]ncc2c1)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C28H26ClN5O4/c1-38-9-6-24(27(37)31-19-4-5-23-17(10-19)14-30-33-23)34-15-22-21(12-25(34)35)20-11-18(29)3-2-16(20)13-28(7-8-28)32-26(22)36/h2-5,10-12,14-15,24H,6-9,13H2,1H3,(H,30,33)(H,31,37)(H,32,36) HDXNHTIPDMDLND-UHFFFAOYSA-N 303800 2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-N-(1H-indazol-5-yl)-4-methoxybutanamide (Stereoisomer Mixture)::US10138236, Example 18 Coagulation factor XI Human 21.0 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303800 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303800&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 121248129 381752531 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582597 COCCC(C(=O)Nc1ccc2c(c1)[nH]n(C)c2=O)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;;;HN;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C29H28ClN5O5/c1-34-28(39)19-6-5-18(12-23(19)33-34)31-27(38)24(7-10-40-2)35-15-22-21(13-25(35)36)20-11-17(30)4-3-16(20)14-29(8-9-29)32-26(22)37/h3-6,11-13,15,24,33H,7-10,14H2,1-2H3,(H,31,38)(H,32,37) DAQPCJFUMAFGPS-UHFFFAOYSA-N 303801 2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-4-methoxy-N-(2-methyl-3-oxo-2,3-dihydro-1H-indazol-6-yl)butanamide (Stereoisomer Mixture)::US10138236, Example 19 Coagulation factor XI Human 8.40 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303801 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303801&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 121247858 381752532 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582598 COCCC(C(=O)Nc1ccc(nc1)C(O)=O)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C27H25ClN4O6/c1-38-9-6-22(25(35)30-17-4-5-21(26(36)37)29-13-17)32-14-20-19(11-23(32)33)18-10-16(28)3-2-15(18)12-27(7-8-27)31-24(20)34/h2-5,10-11,13-14,22H,6-9,12H2,1H3,(H,30,35)(H,31,34)(H,36,37) LAOPVJMWYLRSKK-UHFFFAOYSA-N 303802 5-{[2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-4-methoxybutanoyl]amino}pyridine-2-carboxylic acid (Stereoisomer Mixture)::US10138236, Example 20 Coagulation factor XI Human 47.0 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303802 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303802&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 121247988 381752533 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582599 COCCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C27H26ClN5O5/c1-38-9-6-22(26(37)31-17-4-5-21(24(29)35)30-13-17)33-14-20-19(11-23(33)34)18-10-16(28)3-2-15(18)12-27(7-8-27)32-25(20)36/h2-5,10-11,13-14,22H,6-9,12H2,1H3,(H2,29,35)(H,31,37)(H,32,36) MGDLVIVVZPLDNQ-UHFFFAOYSA-N 303803 5-{[2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-4-methoxybutanoyl]amino}pyridine-2-carboxamide (Stereoisomer Mixture)::US10138236, Example 21 Coagulation factor XI Human 34.0 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303803 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303803&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 121247879 381752534 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582600 COCCC(C(=O)Nc1ccc(s1)C(O)=O)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C26H24ClN3O6S/c1-36-9-6-19(24(33)28-21-5-4-20(37-21)25(34)35)30-13-18-17(11-22(30)31)16-10-15(27)3-2-14(16)12-26(7-8-26)29-23(18)32/h2-5,10-11,13,19H,6-9,12H2,1H3,(H,28,33)(H,29,32)(H,34,35) SCDJLHAYCAFVMW-UHFFFAOYSA-N 303804 5-{[2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-4-methoxybutanoyl]amino}thiophene-2-carboxylic acid (Stereoisomer Mixture)::US10138236, Example 22 Coagulation factor XI Human 4.00 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303804 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303804&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 121247853 381752535 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582601 COCCC(C(=O)Nc1cc(cs1)C(O)=O)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C26H24ClN3O6S/c1-36-7-4-20(24(33)28-21-8-15(13-37-21)25(34)35)30-12-19-18(10-22(30)31)17-9-16(27)3-2-14(17)11-26(5-6-26)29-23(19)32/h2-3,8-10,12-13,20H,4-7,11H2,1H3,(H,28,33)(H,29,32)(H,34,35) LVYYWTCICJFTHG-UHFFFAOYSA-N 303805 5-{[2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-4-methoxybutanoyl]amino}thiophene-3-carboxylic acid (Stereoisomer Mixture)::US10138236, Example 23 Coagulation factor XI Human 100.0 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303805 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303805&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 121247825 381752536 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582602 COCCC(C(=O)Nc1csc(c1)C(O)=O)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C26H24ClN3O6S/c1-36-7-4-20(24(33)28-16-9-21(25(34)35)37-13-16)30-12-19-18(10-22(30)31)17-8-15(27)3-2-14(17)11-26(5-6-26)29-23(19)32/h2-3,8-10,12-13,20H,4-7,11H2,1H3,(H,28,33)(H,29,32)(H,34,35) RLNDJWGABHXOKH-UHFFFAOYSA-N 303806 4-{[2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-4-methoxybutanoyl]amino}thiophene-2-carboxylic acid (Stereoisomer Mixture)::US10138236, Example 24 Coagulation factor XI Human 35.0 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303806 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303806&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 121247932 381752537 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582603 CO[C@H]1CC[C@H](CC(C(=O)Nc2ccc(cc2)C(O)=O)n2cc3c(cc2=O)-c2cc(Cl)ccc2CC2(CC2)NC3=O)CC1 |r,wU:2.1,wD:5.5,$;;;;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;;;$,(6.38,5.01,;5.05,5.78,;3.71,5,;3.71,3.46,;2.38,2.7,;1.05,3.46,;-.29,2.69,;-.29,1.15,;1.05,.38,;1.05,-1.16,;2.38,1.15,;3.71,.38,;5.05,1.15,;6.38,.38,;6.38,-1.16,;5.05,-1.93,;3.71,-1.16,;7.71,-1.92,;9.05,-1.15,;7.71,-3.46,;-1.62,.38,;-2.95,1.15,;-4.29,.38,;-4.29,-1.16,;-2.95,-1.93,;-1.62,-1.16,;-.29,-1.93,;-5.62,-1.93,;-5.62,-3.47,;-6.96,-4.24,;-6.96,-5.78,;-8.29,-3.47,;-8.29,-1.93,;-6.96,-1.16,;-7.91,.01,;-7.51,1.5,;-9.05,1.5,;-8.28,2.83,;-6.17,2.27,;-4.69,1.87,;-3.6,2.96,;1.05,5,;2.38,5.77,)| InChI=1S/C33H34ClN3O6/c1-43-24-10-2-19(3-11-24)14-28(31(40)35-23-8-5-20(6-9-23)32(41)42)37-18-27-26(16-29(37)38)25-15-22(34)7-4-21(25)17-33(12-13-33)36-30(27)39/h4-9,15-16,18-19,24,28H,2-3,10-14,17H2,1H3,(H,35,40)(H,36,39)(H,41,42) QINUWAZYQLMKQU-UHFFFAOYSA-N 303807 4-{[2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-3-(trans-4-methoxycyclohexyl)propanoyl]amino}benzoic acid (Stereoisomer Mixture)::US10138236, Example 25 Coagulation factor XI Human 2.50 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303807 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303807&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 121248151 381752538 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582604 CO[C@H]1CC[C@H](CC(C(=O)Nc2ccc(C(N)=O)c(F)c2)n2cc3c(cc2=O)-c2cc(Cl)ccc2CC2(CC2)NC3=O)CC1 |r,wU:2.1,wD:5.5,$;;;;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;;;$,(6.38,5.01,;5.05,5.78,;3.71,5,;3.71,3.46,;2.38,2.7,;1.05,3.46,;-.29,2.69,;-.29,1.15,;1.05,.38,;1.05,-1.16,;2.38,1.15,;3.71,.38,;3.71,-1.16,;5.05,-1.93,;6.38,-1.16,;7.71,-1.92,;9.05,-1.15,;7.71,-3.46,;6.38,.38,;7.71,1.15,;5.05,1.15,;-1.62,.38,;-2.95,1.15,;-4.29,.38,;-4.29,-1.16,;-2.95,-1.93,;-1.62,-1.16,;-.29,-1.93,;-5.62,-1.93,;-5.62,-3.47,;-6.96,-4.24,;-6.96,-5.78,;-8.29,-3.47,;-8.29,-1.93,;-6.96,-1.16,;-7.91,.01,;-7.51,1.5,;-9.05,1.5,;-8.28,2.83,;-6.17,2.27,;-4.69,1.87,;-3.6,2.96,;1.05,5,;2.38,5.77,)| InChI=1S/C33H34ClFN4O5/c1-44-22-7-2-18(3-8-22)12-28(32(43)37-21-6-9-23(30(36)41)27(35)14-21)39-17-26-25(15-29(39)40)24-13-20(34)5-4-19(24)16-33(10-11-33)38-31(26)42/h4-6,9,13-15,17-18,22,28H,2-3,7-8,10-12,16H2,1H3,(H2,36,41)(H,37,43)(H,38,42) WBDFEEOUOGIVHD-UHFFFAOYSA-N 303808 4-{[2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-3-(trans-4-methoxycyclohexyl)propanoyl]amino}-2-fluorobenzamide (Stereoisomer Mixture)::US10138236, Example 26 Coagulation factor XI Human 34.0 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303808 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303808&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 121247818 381752539 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582605 CO[C@H]1CC[C@H](CC(C(=O)Nc2ccc3[nH]c(=O)[nH]c3c2)n2cc3c(cc2=O)-c2cc(Cl)ccc2CC2(CC2)NC3=O)CC1 |r,wU:2.1,wD:5.5,$;;;;;;;;;;HN;;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;HN;;;;$,(6.03,5.01,;4.69,5.78,;3.36,5,;3.36,3.46,;2.03,2.7,;.69,3.46,;-.64,2.69,;-.64,1.15,;.69,.38,;.69,-1.16,;2.03,1.15,;3.36,.38,;3.36,-1.16,;4.69,-1.93,;6.03,-1.16,;7.49,-1.63,;8.4,-.39,;9.94,-.39,;7.49,.86,;6.03,.38,;4.69,1.15,;-1.97,.38,;-3.31,1.15,;-4.64,.38,;-4.64,-1.16,;-3.31,-1.93,;-1.97,-1.16,;-.64,-1.93,;-5.98,-1.93,;-5.98,-3.47,;-7.31,-4.24,;-7.31,-5.78,;-8.64,-3.47,;-8.64,-1.93,;-7.31,-1.16,;-8.4,-.07,;-8.4,1.47,;-9.94,1.47,;-9.17,2.81,;-7.06,2.24,;-5.04,1.87,;-4.27,3.21,;.69,5,;2.03,5.77,)| InChI=1S/C33H34ClN5O5/c1-44-22-7-2-18(3-8-22)12-28(31(42)35-21-6-9-26-27(14-21)37-32(43)36-26)39-17-25-24(15-29(39)40)23-13-20(34)5-4-19(23)16-33(10-11-33)38-30(25)41/h4-6,9,13-15,17-18,22,28H,2-3,7-8,10-12,16H2,1H3,(H,35,42)(H,38,41)(H2,36,37,43) KKOUJTRQGUTRHQ-UHFFFAOYSA-N 303809 2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-3-(trans-4-methoxycyclohexyl)-N-(2-oxo-2,3-dihydro-1H-benzimidazol-5-yl)propanamide (Stereoisomer Mixture)::US10138236, Example 27 Coagulation factor XI Human 18.0 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303809 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303809&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 121247982 381752540 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582606 OC(=O)c1ccc(NC(=O)C(Cc2ccccc2)n2cc3c(cc2=O)-c2cc(Cl)ccc2CC2(CC2)NC3=O)cc1 |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;;;$| InChI=1S/C32H26ClN3O5/c33-22-9-6-21-17-32(12-13-32)35-29(38)26-18-36(28(37)16-25(26)24(21)15-22)27(14-19-4-2-1-3-5-19)30(39)34-23-10-7-20(8-11-23)31(40)41/h1-11,15-16,18,27H,12-14,17H2,(H,34,39)(H,35,38)(H,40,41) IJIWFVZSETXIFG-UHFFFAOYSA-N 303810 4-{[2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-3-phenylpropanoyl]amino}benzoic acid (Stereoisomer Mixture)::US10138236, Example 28 Coagulation factor XI Human 1.80 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303810 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303810&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 121247962 381752541 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582607 Clc1ccc2CC3(CC3)NC(=O)c3cn(C(Cc4ccccc4)C(=O)Nc4ccc5[nH]c(=O)[nH]c5c4)c(=O)cc3-c2c1 |$;;;;;;;;;HN;;;;;;;;;;;;;;;;HN;;;;;;;;HN;;;;;;;;$| InChI=1S/C32H26ClN5O4/c33-20-7-6-19-16-32(10-11-32)37-29(40)24-17-38(28(39)15-23(24)22(19)13-20)27(12-18-4-2-1-3-5-18)30(41)34-21-8-9-25-26(14-21)36-31(42)35-25/h1-9,13-15,17,27H,10-12,16H2,(H,34,41)(H,37,40)(H2,35,36,42) VUHILQGABHYBOA-UHFFFAOYSA-N 303811 2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-N-(2-oxo-2,3-dihydro-1H-benzimidazol-5-yl)-3-phenylpropanamide (Stereoisomer Mixture)::US10138236, Example 29 Coagulation factor XI Human 4.50 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303811 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303811&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 121247966 381752542 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582608 Cn1cc2cc(NC(=O)C(Cc3ccccc3)n3cc4c(cc3=O)-c3cc(Cl)ccc3CC3(CC3)NC4=O)ccc2n1 |$;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;;;;;$| InChI=1S/C33H28ClN5O3/c1-38-18-22-14-24(9-10-28(22)37-38)35-32(42)29(13-20-5-3-2-4-6-20)39-19-27-26(16-30(39)40)25-15-23(34)8-7-21(25)17-33(11-12-33)36-31(27)41/h2-10,14-16,18-19,29H,11-13,17H2,1H3,(H,35,42)(H,36,41) NCOTWGDMTUCKSK-UHFFFAOYSA-N 303812 2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-N-(2-methyl-2H-indazol-5-yl)-3-phenylpropanamide (Stereoisomer Mixture)::US10138236, Example 30 Coagulation factor XI Human 4.50 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303812 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303812&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 121247985 381752543 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582609 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC(CF)NC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C28H27ClFN5O4/c1-34-14-17-10-19(5-6-24(17)33-34)31-28(38)25(7-8-39-2)35-15-23-22(12-26(35)36)21-11-18(29)4-3-16(21)9-20(13-30)32-27(23)37/h3-6,10-12,14-15,20,25H,7-9,13H2,1-2H3,(H,31,38)(H,32,37) WTECJQOPSGZRRS-UHFFFAOYSA-N 303813 2-[11-Chloro-7-(fluoromethyl)-2,5-dioxo-5,6,7,8-tetrahydropyrido[3,4-e][3]benzazocin-3(2H)-yl]-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Stereoisomer Mixture)::US10138236, Example 31 Coagulation factor XI Human 2.80 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303813 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303813&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 121247976 381752544 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582610 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC(CF)NC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C27H25ClF2N4O5/c1-39-7-6-23(27(38)32-16-4-5-18(25(31)36)22(30)10-16)34-13-21-20(11-24(34)35)19-9-15(28)3-2-14(19)8-17(12-29)33-26(21)37/h2-5,9-11,13,17,23H,6-8,12H2,1H3,(H2,31,36)(H,32,38)(H,33,37) TUSKZVWLXAIZDG-UHFFFAOYSA-N 303814 4-({2-[11-Chloro-7-(fluoromethyl)-2,5-dioxo-5,6,7,8-tetrahydropyrido[3,4-e][3]benzazocin-3(2H)-yl]-4-methoxybutanoyl}amino)-2-fluorobenzamide (Stereoisomer Mixture)::US10138236, Example 32 Coagulation factor XI Human 5.30 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303814 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303814&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 121247977 381752545 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582611 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC(CF)NC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C27H25ClFN3O6/c1-38-9-8-23(26(35)30-18-6-3-15(4-7-18)27(36)37)32-14-22-21(12-24(32)33)20-11-17(28)5-2-16(20)10-19(13-29)31-25(22)34/h2-7,11-12,14,19,23H,8-10,13H2,1H3,(H,30,35)(H,31,34)(H,36,37) XPAARJWVQMOJHJ-UHFFFAOYSA-N 303815 4-({2-[11-Chloro-7-(fluoromethyl)-2,5-dioxo-5,6,7,8-tetrahydropyrido[3,4-e][3]benzazocin-3(2H)-yl]-4-methoxybutanoyl}amino)benzoic acid (Stereoisomer Mixture)::US10138236, Example 33 Coagulation factor XI Human 1.20 US Patent 10.7270/Q2445PH4 aid1796153 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303815 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1357&target=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303815&enzyme=Coagulation+factor+XI&column=ki&startPg=0&Increment=50&submit=Search 121248128 381752546 1 MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV 6I58,5I25,5EOK,5EOD,7QOT,1XX9,4NA8,4NA7,2J8L,2J8J Coagulation factor XI FA11_HUMAN P03951 D3DP64 Q4W5C2 Q9Y495 582612 CCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc2c(cc1=O)-c1cc(Cl)ccc1CNC2=O |$;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C24H20ClN3O5/c1-2-20(23(31)27-16-7-4-13(5-8-16)24(32)33)28-12-19-18(10-21(28)29)17-9-15(25)6-3-14(17)11-26-22(19)30/h3-10,12,20H,2,11H2,1H3,(H,26,30)(H,27,31)(H,32,33) SKGWZOVDJYWHAV-UHFFFAOYSA-N 303783 4-{[2-(10-Chloro-2,5-dioxo-2,5,6,7-tetrahydro-3H-pyrido[3,4-d][2]benzazepin-3-yl)butanoyl]amino}benzoic acid (Stereoisomer Mixture)::US10138236, Example 1 Plasma kallikrein Human >10000 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303783 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303783&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121247947 381752514 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582613 CCC(C(=O)Nc1ccc(cc1)-c1noc(=O)[nH]1)n1cc2c(cc1=O)-c1cc(Cl)ccc1CNC2=O |$;;;;;HN;;;;;;;;;;;;HN;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C25H20ClN5O5/c1-2-20(24(34)28-16-7-4-13(5-8-16)22-29-25(35)36-30-22)31-12-19-18(10-21(31)32)17-9-15(26)6-3-14(17)11-27-23(19)33/h3-10,12,20H,2,11H2,1H3,(H,27,33)(H,28,34)(H,29,30,35) ISVJPGYUZXHMRW-UHFFFAOYSA-N 303784 2-(10-Chloro-2,5-dioxo-2,5,6,7-tetrahydro-3H-pyrido[3,4-d][2]benzazepin-3-yl)-N-[4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl]butanamide (Stereoisomer Mixture)::US10138236, Example 2 Plasma kallikrein Human 4900 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303784 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303784&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 137135831 381752515 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582614 CCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc2c(cc1=O)-c1cc(Cl)ccc1C1(CC1)NC2=O |$;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C26H22ClN3O5/c1-2-21(24(33)28-16-6-3-14(4-7-16)25(34)35)30-13-19-17(12-22(30)31)18-11-15(27)5-8-20(18)26(9-10-26)29-23(19)32/h3-8,11-13,21H,2,9-10H2,1H3,(H,28,33)(H,29,32)(H,34,35) KCGMSSQFQFMUQQ-UHFFFAOYSA-N 303785 4-{[2-(10′-Chloro-2′,5′-dioxo-5′,6′-dihydrospiro[cyclopropane-1,7′-pyrido[3,4-d][2]benzazepine]-3′(2′H)-yl)butanoyl]amino}benzoic acid (Stereoisomer Mixture)::US10138236, Example 3 Plasma kallikrein Human >50000 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303785 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303785&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121247954 381752516 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582615 OC(=O)c1ccc(NC(=O)Cn2cc3c(cc2=O)-c2cc(Cl)ccc2CCNC3=O)cc1 |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;HN;;;;$| InChI=1S/C23H18ClN3O5/c24-15-4-1-13-7-8-25-22(30)19-11-27(21(29)10-18(19)17(13)9-15)12-20(28)26-16-5-2-14(3-6-16)23(31)32/h1-6,9-11H,7-8,12H2,(H,25,30)(H,26,28)(H,31,32) YHCVQIPIKWVWDD-UHFFFAOYSA-N 303786 4-{[(11-Chloro-2,5-dioxo-5,6,7,8-tetrahydropyrido[3,4-e][3]benzazocin-3(2H)-yl)acetyl]amino}benzoic acid::US10138236, Example 4 Plasma kallikrein Human 18000 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303786 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303786&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121248291 381752517 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582616 Clc1ccc2CCNC(=O)c3cn(CC(=O)Nc4ccc(cc4)-c4noc(=O)[nH]4)c(=O)cc3-c2c1 |$;;;;;;;HN;;;;;;;;;HN;;;;;;;;;;;;HN;;;;;;$| InChI=1S/C24H18ClN5O5/c25-15-4-1-13-7-8-26-23(33)19-11-30(21(32)10-18(19)17(13)9-15)12-20(31)27-16-5-2-14(3-6-16)22-28-24(34)35-29-22/h1-6,9-11H,7-8,12H2,(H,26,33)(H,27,31)(H,28,29,34) UPXBPQOTPKHXLR-UHFFFAOYSA-N 303787 2-(11-Chloro-2,5-dioxo-5,6,7,8-tetrahydropyrido[3,4-e][3]benzazocin-3(2H)-yl)-N-[4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl]acetamide::US10138236, Example 5 Plasma kallikrein Human 8300 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303787 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303787&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 137135834 381752518 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582617 CCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc2c(cc1=O)-c1cc(Cl)ccc1CCNC2=O |$;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C25H22ClN3O5/c1-2-21(24(32)28-17-7-4-15(5-8-17)25(33)34)29-13-20-19(12-22(29)30)18-11-16(26)6-3-14(18)9-10-27-23(20)31/h3-8,11-13,21H,2,9-10H2,1H3,(H,27,31)(H,28,32)(H,33,34) QTIMNPKDOKJHOR-UHFFFAOYSA-N 303788 4-{[2-(11-Chloro-2,5-dioxo-5,6,7,8-tetrahydropyrido[3,4-e][3]benzazocin-3(2H)-yl)butanoyl]amino}benzoic acid (Stereoisomer Mixture)::US10138236, Example 6 Plasma kallikrein Human 1900 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303788 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303788&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121247931 381752519 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582618 CCC(C(=O)Nc1ccc(cc1)-c1noc(=O)[nH]1)n1cc2c(cc1=O)-c1cc(Cl)ccc1CCNC2=O |$;;;;;HN;;;;;;;;;;;;HN;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C26H22ClN5O5/c1-2-21(25(35)29-17-7-4-15(5-8-17)23-30-26(36)37-31-23)32-13-20-19(12-22(32)33)18-11-16(27)6-3-14(18)9-10-28-24(20)34/h3-8,11-13,21H,2,9-10H2,1H3,(H,28,34)(H,29,35)(H,30,31,36) JIKIDROQLCJHCV-UHFFFAOYSA-N 303789 2-(11-Chloro-2,5-dioxo-5,6,7,8-tetrahydropyrido[3,4-e][3]benzazocin-3(2H)-yl)-N-[4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl]butanamide (Stereoisomer Mixture)::US10138236, Example 7 Plasma kallikrein Human 3300 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303789 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303789&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 137135835 381752520 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582619 CC(C)CC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc2c(cc1=O)-c1cc(Cl)ccc1CCNC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C27H26ClN3O5/c1-15(2)11-23(26(34)30-19-7-4-17(5-8-19)27(35)36)31-14-22-21(13-24(31)32)20-12-18(28)6-3-16(20)9-10-29-25(22)33/h3-8,12-15,23H,9-11H2,1-2H3,(H,29,33)(H,30,34)(H,35,36) NUGGTDIZDRCFKE-UHFFFAOYSA-N 303790 4-{[2-(11-Chloro-2,5-dioxo-5,6,7,8-tetrahydropyrido[3,4-e][3]benzazocin-3(2H)-yl)-4-methylpentanoyl]amino}benzoic acid (Stereoisomer Mixture)::US10138236, Example 8 Plasma kallikrein Human 680 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303790 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303790&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 130446977 381752521 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582620 CC(C)CC(C(=O)Nc1ccc(cc1)-c1noc(=O)[nH]1)n1cc2c(cc1=O)-c1cc(Cl)ccc1CCNC2=O |$;;;;;;;HN;;;;;;;;;;;;HN;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C28H26ClN5O5/c1-15(2)11-23(27(37)31-19-7-4-17(5-8-19)25-32-28(38)39-33-25)34-14-22-21(13-24(34)35)20-12-18(29)6-3-16(20)9-10-30-26(22)36/h3-8,12-15,23H,9-11H2,1-2H3,(H,30,36)(H,31,37)(H,32,33,38) XMCVCGZQOZMSLX-UHFFFAOYSA-N 303791 2-(11-Chloro-2,5-dioxo-5,6,7,8-tetrahydropyrido[3,4-e][3]benzazocin-3(2H)-yl)-4-methyl-N-[4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl]pentanamide (Stereoisomer Mixture)::US10138236, Example 9 Plasma kallikrein Human 3800 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303791 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303791&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 137198183 381752522 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582621 CCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C27H24ClN3O5/c1-2-22(25(34)29-18-7-4-15(5-8-18)26(35)36)31-14-21-20(12-23(31)32)19-11-17(28)6-3-16(19)13-27(9-10-27)30-24(21)33/h3-8,11-12,14,22H,2,9-10,13H2,1H3,(H,29,34)(H,30,33)(H,35,36) SLECLLUJAMLAFG-UHFFFAOYSA-N 303792 4-{[2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)butanoyl]amino}benzoic acid (Stereoisomer Mixture)::US10138236, Example 10 Plasma kallikrein Human 2100 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303792 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303792&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121248294 381752523 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582622 CCC(C(=O)Nc1ccc(cc1)-c1noc(=O)[nH]1)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;HN;;;;;;;;;;;;HN;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C28H24ClN5O5/c1-2-22(26(37)30-18-7-4-15(5-8-18)24-31-27(38)39-33-24)34-14-21-20(12-23(34)35)19-11-17(29)6-3-16(19)13-28(9-10-28)32-25(21)36/h3-8,11-12,14,22H,2,9-10,13H2,1H3,(H,30,37)(H,32,36)(H,31,33,38) ZUPOJXBRFRVQEB-UHFFFAOYSA-N 303793 2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-N-[4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl]butanamide (Stereoisomer Mixture)::US10138236, Example 11 Plasma kallikrein Human 1700 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303793 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303793&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 137135832 381752524 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582623 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C28H26ClN3O6/c1-38-11-8-23(26(35)30-19-6-3-16(4-7-19)27(36)37)32-15-22-21(13-24(32)33)20-12-18(29)5-2-17(20)14-28(9-10-28)31-25(22)34/h2-7,12-13,15,23H,8-11,14H2,1H3,(H,30,35)(H,31,34)(H,36,37) XQFUNGTWELOWHU-UHFFFAOYSA-N 303794 4-{[2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-4-methoxybutanoyl]amino}benzoic acid (Stereoisomer Mixture)::US10138236, Example 12 Plasma kallikrein Human 390 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303794 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303794&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121247878 381752525 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582624 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C28H26ClFN4O5/c1-39-9-6-23(27(38)32-17-4-5-18(25(31)36)22(30)11-17)34-14-21-20(12-24(34)35)19-10-16(29)3-2-15(19)13-28(7-8-28)33-26(21)37/h2-5,10-12,14,23H,6-9,13H2,1H3,(H2,31,36)(H,32,38)(H,33,37) BPCDFQQYUDAWIS-UHFFFAOYSA-N 303795 4-{[2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-4-methoxybutanoyl]amino}-2-fluorobenzamide (Stereoisomer Mixture)::US10138236, Example 13 Plasma kallikrein Human 780 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303795 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303795&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121247960 381752526 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582625 COCCC(C(=O)Nc1ccc2[nH]c(=O)[nH]c2c1)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;;;HN;;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C28H26ClN5O5/c1-39-9-6-23(26(37)30-17-4-5-21-22(11-17)32-27(38)31-21)34-14-20-19(12-24(34)35)18-10-16(29)3-2-15(18)13-28(7-8-28)33-25(20)36/h2-5,10-12,14,23H,6-9,13H2,1H3,(H,30,37)(H,33,36)(H2,31,32,38) XTKDBGPBQRDAJF-UHFFFAOYSA-N 303796 2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-4-methoxy-N-(2-oxo-2,3-dihydro-1H-benzimidazol-5-yl)butanamide (Stereoisomer Mixture)::US10138236, Example 14 Plasma kallikrein Human 230 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303796 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303796&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121248288 381752527 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582626 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C29H28ClN5O4/c1-34-15-18-11-20(5-6-24(18)33-34)31-28(38)25(7-10-39-2)35-16-23-22(13-26(35)36)21-12-19(30)4-3-17(21)14-29(8-9-29)32-27(23)37/h3-6,11-13,15-16,25H,7-10,14H2,1-2H3,(H,31,38)(H,32,37) KLDJEVDWFKQWAE-UHFFFAOYSA-N 303797 2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Stereoisomer Mixture)::US10138236, Example 15 Plasma kallikrein Human 240 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303797 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303797&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121248295 381752528 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582627 COCCC(C(=O)Nc1ccn2nccc2c1)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C28H26ClN5O4/c1-38-11-6-24(27(37)31-19-5-10-34-20(13-19)4-9-30-34)33-16-23-22(14-25(33)35)21-12-18(29)3-2-17(21)15-28(7-8-28)32-26(23)36/h2-5,9-10,12-14,16,24H,6-8,11,15H2,1H3,(H,31,37)(H,32,36) FJPYLKOGJOUMKM-UHFFFAOYSA-N 303798 2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-4-methoxy-N-(pyrazolo[1,5-a]pyridin-5-yl)butanamide (Stereoisomer Mixture)::US10138236, Example 16 Plasma kallikrein Human 210 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303798 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303798&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121248130 381752529 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582628 COCCC(C(=O)Nc1ccc2nccn2c1)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C28H26ClN5O4/c1-38-11-6-23(27(37)31-19-4-5-24-30-9-10-33(24)15-19)34-16-22-21(13-25(34)35)20-12-18(29)3-2-17(20)14-28(7-8-28)32-26(22)36/h2-5,9-10,12-13,15-16,23H,6-8,11,14H2,1H3,(H,31,37)(H,32,36) LJUIKBIWSCZQIA-UHFFFAOYSA-N 303799 2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-N-(imidazo[1,2-a]pyridin-6-yl)-4-methoxybutanamide (Stereoisomer Mixture)::US10138236, Example 17 Plasma kallikrein Human 1200 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303799 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303799&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121247961 381752530 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582629 COCCC(C(=O)Nc1ccc2[nH]ncc2c1)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C28H26ClN5O4/c1-38-9-6-24(27(37)31-19-4-5-23-17(10-19)14-30-33-23)34-15-22-21(12-25(34)35)20-11-18(29)3-2-16(20)13-28(7-8-28)32-26(22)36/h2-5,10-12,14-15,24H,6-9,13H2,1H3,(H,30,33)(H,31,37)(H,32,36) HDXNHTIPDMDLND-UHFFFAOYSA-N 303800 2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-N-(1H-indazol-5-yl)-4-methoxybutanamide (Stereoisomer Mixture)::US10138236, Example 18 Plasma kallikrein Human 330 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303800 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303800&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121248129 381752531 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582630 COCCC(C(=O)Nc1ccc2c(c1)[nH]n(C)c2=O)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;;;HN;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C29H28ClN5O5/c1-34-28(39)19-6-5-18(12-23(19)33-34)31-27(38)24(7-10-40-2)35-15-22-21(13-25(35)36)20-11-17(30)4-3-16(20)14-29(8-9-29)32-26(22)37/h3-6,11-13,15,24,33H,7-10,14H2,1-2H3,(H,31,38)(H,32,37) DAQPCJFUMAFGPS-UHFFFAOYSA-N 303801 2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-4-methoxy-N-(2-methyl-3-oxo-2,3-dihydro-1H-indazol-6-yl)butanamide (Stereoisomer Mixture)::US10138236, Example 19 Plasma kallikrein Human 230 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303801 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303801&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121247858 381752532 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582631 COCCC(C(=O)Nc1ccc(nc1)C(O)=O)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C27H25ClN4O6/c1-38-9-6-22(25(35)30-17-4-5-21(26(36)37)29-13-17)32-14-20-19(11-23(32)33)18-10-16(28)3-2-15(18)12-27(7-8-27)31-24(20)34/h2-5,10-11,13-14,22H,6-9,12H2,1H3,(H,30,35)(H,31,34)(H,36,37) LAOPVJMWYLRSKK-UHFFFAOYSA-N 303802 5-{[2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-4-methoxybutanoyl]amino}pyridine-2-carboxylic acid (Stereoisomer Mixture)::US10138236, Example 20 Plasma kallikrein Human 4500 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303802 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303802&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121247988 381752533 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582632 COCCC(C(=O)Nc1ccc(nc1)C(N)=O)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C27H26ClN5O5/c1-38-9-6-22(26(37)31-17-4-5-21(24(29)35)30-13-17)33-14-20-19(11-23(33)34)18-10-16(28)3-2-15(18)12-27(7-8-27)32-25(20)36/h2-5,10-11,13-14,22H,6-9,12H2,1H3,(H2,29,35)(H,31,37)(H,32,36) MGDLVIVVZPLDNQ-UHFFFAOYSA-N 303803 5-{[2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-4-methoxybutanoyl]amino}pyridine-2-carboxamide (Stereoisomer Mixture)::US10138236, Example 21 Plasma kallikrein Human 910 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303803 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303803&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121247879 381752534 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582633 COCCC(C(=O)Nc1ccc(s1)C(O)=O)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C26H24ClN3O6S/c1-36-9-6-19(24(33)28-21-5-4-20(37-21)25(34)35)30-13-18-17(11-22(30)31)16-10-15(27)3-2-14(16)12-26(7-8-26)29-23(18)32/h2-5,10-11,13,19H,6-9,12H2,1H3,(H,28,33)(H,29,32)(H,34,35) SCDJLHAYCAFVMW-UHFFFAOYSA-N 303804 5-{[2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-4-methoxybutanoyl]amino}thiophene-2-carboxylic acid (Stereoisomer Mixture)::US10138236, Example 22 Plasma kallikrein Human 340 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303804 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303804&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121247853 381752535 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582634 COCCC(C(=O)Nc1cc(cs1)C(O)=O)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C26H24ClN3O6S/c1-36-7-4-20(24(33)28-21-8-15(13-37-21)25(34)35)30-12-19-18(10-22(30)31)17-9-16(27)3-2-14(17)11-26(5-6-26)29-23(19)32/h2-3,8-10,12-13,20H,4-7,11H2,1H3,(H,28,33)(H,29,32)(H,34,35) LVYYWTCICJFTHG-UHFFFAOYSA-N 303805 5-{[2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-4-methoxybutanoyl]amino}thiophene-3-carboxylic acid (Stereoisomer Mixture)::US10138236, Example 23 Plasma kallikrein Human 3900 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303805 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303805&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121247825 381752536 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582635 COCCC(C(=O)Nc1csc(c1)C(O)=O)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC1(CC1)NC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C26H24ClN3O6S/c1-36-7-4-20(24(33)28-16-9-21(25(34)35)37-13-16)30-12-19-18(10-22(30)31)17-8-15(27)3-2-14(17)11-26(5-6-26)29-23(19)32/h2-3,8-10,12-13,20H,4-7,11H2,1H3,(H,28,33)(H,29,32)(H,34,35) RLNDJWGABHXOKH-UHFFFAOYSA-N 303806 4-{[2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-4-methoxybutanoyl]amino}thiophene-2-carboxylic acid (Stereoisomer Mixture)::US10138236, Example 24 Plasma kallikrein Human 800 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303806 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303806&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121247932 381752537 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582636 CO[C@H]1CC[C@H](CC(C(=O)Nc2ccc(cc2)C(O)=O)n2cc3c(cc2=O)-c2cc(Cl)ccc2CC2(CC2)NC3=O)CC1 |r,wU:2.1,wD:5.5,$;;;;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;;;$,(6.38,5.01,;5.05,5.78,;3.71,5,;3.71,3.46,;2.38,2.7,;1.05,3.46,;-.29,2.69,;-.29,1.15,;1.05,.38,;1.05,-1.16,;2.38,1.15,;3.71,.38,;5.05,1.15,;6.38,.38,;6.38,-1.16,;5.05,-1.93,;3.71,-1.16,;7.71,-1.92,;9.05,-1.15,;7.71,-3.46,;-1.62,.38,;-2.95,1.15,;-4.29,.38,;-4.29,-1.16,;-2.95,-1.93,;-1.62,-1.16,;-.29,-1.93,;-5.62,-1.93,;-5.62,-3.47,;-6.96,-4.24,;-6.96,-5.78,;-8.29,-3.47,;-8.29,-1.93,;-6.96,-1.16,;-7.91,.01,;-7.51,1.5,;-9.05,1.5,;-8.28,2.83,;-6.17,2.27,;-4.69,1.87,;-3.6,2.96,;1.05,5,;2.38,5.77,)| InChI=1S/C33H34ClN3O6/c1-43-24-10-2-19(3-11-24)14-28(31(40)35-23-8-5-20(6-9-23)32(41)42)37-18-27-26(16-29(37)38)25-15-22(34)7-4-21(25)17-33(12-13-33)36-30(27)39/h4-9,15-16,18-19,24,28H,2-3,10-14,17H2,1H3,(H,35,40)(H,36,39)(H,41,42) QINUWAZYQLMKQU-UHFFFAOYSA-N 303807 4-{[2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-3-(trans-4-methoxycyclohexyl)propanoyl]amino}benzoic acid (Stereoisomer Mixture)::US10138236, Example 25 Plasma kallikrein Human 370 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303807 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303807&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121248151 381752538 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582637 CO[C@H]1CC[C@H](CC(C(=O)Nc2ccc(C(N)=O)c(F)c2)n2cc3c(cc2=O)-c2cc(Cl)ccc2CC2(CC2)NC3=O)CC1 |r,wU:2.1,wD:5.5,$;;;;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;;;$,(6.38,5.01,;5.05,5.78,;3.71,5,;3.71,3.46,;2.38,2.7,;1.05,3.46,;-.29,2.69,;-.29,1.15,;1.05,.38,;1.05,-1.16,;2.38,1.15,;3.71,.38,;3.71,-1.16,;5.05,-1.93,;6.38,-1.16,;7.71,-1.92,;9.05,-1.15,;7.71,-3.46,;6.38,.38,;7.71,1.15,;5.05,1.15,;-1.62,.38,;-2.95,1.15,;-4.29,.38,;-4.29,-1.16,;-2.95,-1.93,;-1.62,-1.16,;-.29,-1.93,;-5.62,-1.93,;-5.62,-3.47,;-6.96,-4.24,;-6.96,-5.78,;-8.29,-3.47,;-8.29,-1.93,;-6.96,-1.16,;-7.91,.01,;-7.51,1.5,;-9.05,1.5,;-8.28,2.83,;-6.17,2.27,;-4.69,1.87,;-3.6,2.96,;1.05,5,;2.38,5.77,)| InChI=1S/C33H34ClFN4O5/c1-44-22-7-2-18(3-8-22)12-28(32(43)37-21-6-9-23(30(36)41)27(35)14-21)39-17-26-25(15-29(39)40)24-13-20(34)5-4-19(24)16-33(10-11-33)38-31(26)42/h4-6,9,13-15,17-18,22,28H,2-3,7-8,10-12,16H2,1H3,(H2,36,41)(H,37,43)(H,38,42) WBDFEEOUOGIVHD-UHFFFAOYSA-N 303808 4-{[2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-3-(trans-4-methoxycyclohexyl)propanoyl]amino}-2-fluorobenzamide (Stereoisomer Mixture)::US10138236, Example 26 Plasma kallikrein Human 740 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303808 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303808&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121247818 381752539 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582638 CO[C@H]1CC[C@H](CC(C(=O)Nc2ccc3[nH]c(=O)[nH]c3c2)n2cc3c(cc2=O)-c2cc(Cl)ccc2CC2(CC2)NC3=O)CC1 |r,wU:2.1,wD:5.5,$;;;;;;;;;;HN;;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;HN;;;;$,(6.03,5.01,;4.69,5.78,;3.36,5,;3.36,3.46,;2.03,2.7,;.69,3.46,;-.64,2.69,;-.64,1.15,;.69,.38,;.69,-1.16,;2.03,1.15,;3.36,.38,;3.36,-1.16,;4.69,-1.93,;6.03,-1.16,;7.49,-1.63,;8.4,-.39,;9.94,-.39,;7.49,.86,;6.03,.38,;4.69,1.15,;-1.97,.38,;-3.31,1.15,;-4.64,.38,;-4.64,-1.16,;-3.31,-1.93,;-1.97,-1.16,;-.64,-1.93,;-5.98,-1.93,;-5.98,-3.47,;-7.31,-4.24,;-7.31,-5.78,;-8.64,-3.47,;-8.64,-1.93,;-7.31,-1.16,;-8.4,-.07,;-8.4,1.47,;-9.94,1.47,;-9.17,2.81,;-7.06,2.24,;-5.04,1.87,;-4.27,3.21,;.69,5,;2.03,5.77,)| InChI=1S/C33H34ClN5O5/c1-44-22-7-2-18(3-8-22)12-28(31(42)35-21-6-9-26-27(14-21)37-32(43)36-26)39-17-25-24(15-29(39)40)23-13-20(34)5-4-19(23)16-33(10-11-33)38-30(25)41/h4-6,9,13-15,17-18,22,28H,2-3,7-8,10-12,16H2,1H3,(H,35,42)(H,38,41)(H2,36,37,43) KKOUJTRQGUTRHQ-UHFFFAOYSA-N 303809 2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-3-(trans-4-methoxycyclohexyl)-N-(2-oxo-2,3-dihydro-1H-benzimidazol-5-yl)propanamide (Stereoisomer Mixture)::US10138236, Example 27 Plasma kallikrein Human 250 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303809 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303809&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121247982 381752540 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582639 OC(=O)c1ccc(NC(=O)C(Cc2ccccc2)n2cc3c(cc2=O)-c2cc(Cl)ccc2CC2(CC2)NC3=O)cc1 |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;;;$| InChI=1S/C32H26ClN3O5/c33-22-9-6-21-17-32(12-13-32)35-29(38)26-18-36(28(37)16-25(26)24(21)15-22)27(14-19-4-2-1-3-5-19)30(39)34-23-10-7-20(8-11-23)31(40)41/h1-11,15-16,18,27H,12-14,17H2,(H,34,39)(H,35,38)(H,40,41) IJIWFVZSETXIFG-UHFFFAOYSA-N 303810 4-{[2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-3-phenylpropanoyl]amino}benzoic acid (Stereoisomer Mixture)::US10138236, Example 28 Plasma kallikrein Human 55.0 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303810 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303810&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121247962 381752541 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582640 Clc1ccc2CC3(CC3)NC(=O)c3cn(C(Cc4ccccc4)C(=O)Nc4ccc5[nH]c(=O)[nH]c5c4)c(=O)cc3-c2c1 |$;;;;;;;;;HN;;;;;;;;;;;;;;;;HN;;;;;;;;HN;;;;;;;;$| InChI=1S/C32H26ClN5O4/c33-20-7-6-19-16-32(10-11-32)37-29(40)24-17-38(28(39)15-23(24)22(19)13-20)27(12-18-4-2-1-3-5-18)30(41)34-21-8-9-25-26(14-21)36-31(42)35-25/h1-9,13-15,17,27H,10-12,16H2,(H,34,41)(H,37,40)(H2,35,36,42) VUHILQGABHYBOA-UHFFFAOYSA-N 303811 2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-N-(2-oxo-2,3-dihydro-1H-benzimidazol-5-yl)-3-phenylpropanamide (Stereoisomer Mixture)::US10138236, Example 29 Plasma kallikrein Human 42.0 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303811 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303811&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121247966 381752542 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582641 Cn1cc2cc(NC(=O)C(Cc3ccccc3)n3cc4c(cc3=O)-c3cc(Cl)ccc3CC3(CC3)NC4=O)ccc2n1 |$;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;;;;;$| InChI=1S/C33H28ClN5O3/c1-38-18-22-14-24(9-10-28(22)37-38)35-32(42)29(13-20-5-3-2-4-6-20)39-19-27-26(16-30(39)40)25-15-23(34)8-7-21(25)17-33(11-12-33)36-31(27)41/h2-10,14-16,18-19,29H,11-13,17H2,1H3,(H,35,42)(H,36,41) NCOTWGDMTUCKSK-UHFFFAOYSA-N 303812 2-(11′-Chloro-2′,5′-dioxo-2′,5′,6′,8′-tetrahydro-3′H-spiro[cyclopropane-1,7′-pyrido[3,4-e][3]benzazocine]-3′-yl)-N-(2-methyl-2H-indazol-5-yl)-3-phenylpropanamide (Stereoisomer Mixture)::US10138236, Example 30 Plasma kallikrein Human 45.0 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303812 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303812&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121247985 381752543 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582642 COCCC(C(=O)Nc1ccc2nn(C)cc2c1)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC(CF)NC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C28H27ClFN5O4/c1-34-14-17-10-19(5-6-24(17)33-34)31-28(38)25(7-8-39-2)35-15-23-22(12-26(35)36)21-11-18(29)4-3-16(21)9-20(13-30)32-27(23)37/h3-6,10-12,14-15,20,25H,7-9,13H2,1-2H3,(H,31,38)(H,32,37) WTECJQOPSGZRRS-UHFFFAOYSA-N 303813 2-[11-Chloro-7-(fluoromethyl)-2,5-dioxo-5,6,7,8-tetrahydropyrido[3,4-e][3]benzazocin-3(2H)-yl]-4-methoxy-N-(2-methyl-2H-indazol-5-yl)butanamide (Stereoisomer Mixture)::US10138236, Example 31 Plasma kallikrein Human 42.0 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303813 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303813&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121247976 381752544 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582643 COCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC(CF)NC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C27H25ClF2N4O5/c1-39-7-6-23(27(38)32-16-4-5-18(25(31)36)22(30)10-16)34-13-21-20(11-24(34)35)19-9-15(28)3-2-14(19)8-17(12-29)33-26(21)37/h2-5,9-11,13,17,23H,6-8,12H2,1H3,(H2,31,36)(H,32,38)(H,33,37) TUSKZVWLXAIZDG-UHFFFAOYSA-N 303814 4-({2-[11-Chloro-7-(fluoromethyl)-2,5-dioxo-5,6,7,8-tetrahydropyrido[3,4-e][3]benzazocin-3(2H)-yl]-4-methoxybutanoyl}amino)-2-fluorobenzamide (Stereoisomer Mixture)::US10138236, Example 32 Plasma kallikrein Human 100.0 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303814 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303814&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121247977 381752545 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 582644 COCCC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc2c(cc1=O)-c1cc(Cl)ccc1CC(CF)NC2=O |$;;;;;;;HN;;;;;;;;;;;;;;;;;;;;;;;;;;;;HN;;$| InChI=1S/C27H25ClFN3O6/c1-38-9-8-23(26(35)30-18-6-3-15(4-7-18)27(36)37)32-14-22-21(12-24(32)33)20-11-17(28)5-2-16(20)10-19(13-29)31-25(22)34/h2-7,11-12,14,19,23H,8-10,13H2,1H3,(H,30,35)(H,31,34)(H,36,37) XPAARJWVQMOJHJ-UHFFFAOYSA-N 303815 4-({2-[11-Chloro-7-(fluoromethyl)-2,5-dioxo-5,6,7,8-tetrahydropyrido[3,4-e][3]benzazocin-3(2H)-yl]-4-methoxybutanoyl}amino)benzoic acid (Stereoisomer Mixture)::US10138236, Example 33 Plasma kallikrein Human 97.0 US Patent 10.7270/Q2445PH4 aid1796154 US10138236 Rohrig, S; Hillisch, A; Heitmeier, S; Schmidt, MV; Schlemmer, K; Tersteegen, A; Schafer, M; Teller, H; Jimenez Nunez, E 11/27/2018 3/29/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=303815 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=303815&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121248128 381752546 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6T7P,7N7X Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3